A NEW chemical entity fixed dose combination product has had an Australian Public Assessment Report (AusPAR) posted by the Therapeutic Goods Administration.
Orkambi 200/125 (lumacaftor/ivacaftor) is a cystic fibrosis (CF) treatment from Vertex Pharmaceuticals.
For details see www.tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Sep 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Sep 16